Printable: FDA Approves Kyprolis® (Carfilzomib) for Combination Use in the Treatment of Patients with Relapsed Multiple Myeloma

FDA Approves Kyprolis® (Carfilzomib) for Combination Use in the Treatment of Patients with Relapsed Multiple Myeloma (https://www.myeloma.org/article/fda-approves-kyprolis-combination-use)

Source URL: https://www.myeloma.org/article/fda-approves-kyprolis-combination-use